Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus
- PMID: 12860946
- DOI: 10.1200/JCO.2003.03.055
Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus
Abstract
Purpose: To assess the long-term toxicity after definitive chemoradiotherapy (CRT) for squamous cell carcinoma (SCC) of the esophagus.
Patients and methods: Patients newly diagnosed with SCC of the esophagus and treated with definitive CRT between 1992 and 1999 in our institution were recruited from our database on the basis of the following criteria: age </= 75 years, performance status (PS; based on the Eastern Cooperative Oncology Group scale) 0 to 2, and clinical tumor-node-metastasis system stage I to IVA. The CRT consisted of two cycles of cisplatin 40 mg/m2 on days 1 and 8, and continuous infusion of fluorouracil 400 mg/m2/d on days 1 to 5 and 8 to 12, repeated every 5 weeks with concurrent radiotherapy of 60 Gy in 30 fractions. For the assessment of toxicity, the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer late radiation morbidity scoring scheme was adopted.
Results: A total of 139 patients were recruited, and their characteristics were as follows: median age, 62 years (range, 38 to 75 years); 121 males and 18 females; 96 patients PS 0, 42 patients PS 1, and one patient PS 2; 15 patients T1, 11 patients T2, 60 patients T3, and 53 patients T4; and 101 patients M0, 38 patients M1a. With a median follow-up of 53 months, the median survival time and 5-year survival rate were 21 months and 29%, respectively. Of 78 patients with complete remission, two patients died as a result of acute myocardial infarction. Grade 2, 3, and 4 late toxicities occurred with the following incidences: pericarditis in eight patients, seven patients, and one patient, respectively; heart failure in zero, zero, and two patients; pleural effusion in seven, eight, and zero patients; and radiation pneumonitis in one patient, three patients, and zero patients, respectively.
Conclusion: Definitive CRT for SCC of the esophagus is effective with substantial toxicities. Additional investigation to minimize the normal tissue toxicities is warranted.
Similar articles
-
Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma.Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):122-8. doi: 10.1016/j.ijrobp.2008.10.075. Epub 2009 Mar 26. Int J Radiat Oncol Biol Phys. 2009. PMID: 19327900
-
Elective nodal irradiation (ENI) in definitive chemoradiotherapy (CRT) for squamous cell carcinoma of the thoracic esophagus.Radiother Oncol. 2009 Aug;92(2):266-9. doi: 10.1016/j.radonc.2008.09.025. Epub 2008 Oct 24. Radiother Oncol. 2009. PMID: 18952308
-
Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906).Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):684-90. doi: 10.1016/j.ijrobp.2010.06.033. Epub 2010 Oct 6. Int J Radiat Oncol Biol Phys. 2011. PMID: 20932658 Clinical Trial.
-
Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer.J Clin Oncol. 2005 Jun 1;23(16):3760-7. doi: 10.1200/JCO.2005.09.108. Epub 2005 Apr 18. J Clin Oncol. 2005. PMID: 15837967 Review.
-
Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.Dis Esophagus. 2015 Oct;28(7):612-8. doi: 10.1111/dote.12242. Epub 2014 May 27. Dis Esophagus. 2015. PMID: 24863560 Review.
Cited by
-
Current endoscopic methods of radical therapy in early esophageal cancer.J Med Life. 2015 Apr-Jun;8(2):150-6. J Med Life. 2015. PMID: 25866570 Free PMC article. Review.
-
Clinical outcomes of radiotherapy for esophageal cancer between 2004 and 2008: the second survey of the Japanese Radiation Oncology Study Group (JROSG).Int J Clin Oncol. 2016 Feb;21(1):88-94. doi: 10.1007/s10147-015-0872-x. Epub 2015 Jul 16. Int J Clin Oncol. 2016. PMID: 26178368
-
Effect of dose-escalation of 5-fluorouracil on circadian variability of its pharmacokinetics in Japanese patients with Stage III/IVa esophageal squamous cell carcinoma.Int J Med Sci. 2010 Jan 31;7(1):48-54. doi: 10.7150/ijms.7.48. Int J Med Sci. 2010. PMID: 20151048 Free PMC article. Clinical Trial.
-
Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society: part 2.Esophagus. 2019 Jan;16(1):25-43. doi: 10.1007/s10388-018-0642-8. Epub 2018 Aug 31. Esophagus. 2019. PMID: 30171414 Free PMC article. No abstract available.
-
Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma.J Gastroenterol. 2006 May;41(5):425-32. doi: 10.1007/s00535-006-1771-8. J Gastroenterol. 2006. PMID: 16799883
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials